1.Zhang Y, Heym B, Allen B, Young D, and Cole S. (1992) The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis [Comment]. Nature (London) 358: 591-593.
2.Scorpio A and Zhang Y (1996) Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus [Comment]. Nature Med 2:662-667.
3.Shi W, Zhang X, Jiang X, Yuan H, Lee J, Barry CE 3rd, Wang H, Zhang W, Zhang Y (2011). Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis [Comment]. Science 333:1630-1632.
4.Zhang S, Chen J, Shi W, Liu W, Zhang WH, Zhang Y (2013). Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerging Microbes & Infections (Nature Publishing Group) 2, e34; doi:10.1038/emi.2013.38
5.Zhang Y (2014). Persisters, Persistent Infections and the Yin-Yang Model. Emerging Microbes & Infections (Nature Publishing Group), 3, e3; doi:10.1038/emi.2014.3 (featured in Nature Outlook special issue on Antibiotics: http://www.nature.com/nature/outlook/antibiotics/?WT.ec_id=NATURE-20140501)
6.Glover W, Yang Y. and Zhang Y (2009). Insights into the Molecular Basis of L-Form Formation and Survival in Escherichia coli. PLoS One. Oct6;4(10):e7316.
7.Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E, Zhang Y (2007). Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA, 104: 16158-16163.
8.Zhang Y. (2012). Metronidazole validates drugs targeting hypoxic bacteria for improved treatment of tuberculosis. Proc. Natl. Acad. Sci. USA. 109: 13890-13891.
9.Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Schafbauer T, Huttner AJ, Huang Y, Carson RE, Zhang Y, Sullivan D, Piepmeier JM, Saltzman WM (2013). Highly penetrative nanocarriers loaded with drugs targeted to resistant cells improve treatment of glioblastoma. Proc. Natl. Acad. Sci. USA, 110:11751-11756.
10.Yin X，Zhou J, Jie C, Xing D, Zhang Y (2004). Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549, Life Sciences, 2004, 75: 2233–2244.
11.Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E, Zhang Y (2007). Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA, 104: 16158-16163。
12.Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y (2008). NF-kB pathway inhibitors preferentially inhibit breast cancer stem cells. Breast Cancer Research and Treatment, 111:419-427.
13.Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Yin D, and Zhang Y (2009). Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model. Breast Cancer Research and Treatment, 115: 269-277.
